Related Experiment Video
Updated: Jun 7, 2025
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
Published on: July 16, 2021
[Current Landscape of Tofersen in SOD-1-associated Amyotrophic Lateral Sclerosis]
Taro Ishiguro1, Tetsuya Nagata, Takanori Yokota
1Department of Neurology and Neurological Science, Institute of Science Tokyo.
Abstract:
Since the identification, in 1993, of the causative gene for familial amyotrophic lateral sclerosis (ALS), which is associated with SOD1 mutations, research has focused on the pathogenesis and therapeutics of ALS for more than 30 years. Tofersen, a highly anticipated gene-specific therapy that has been aligned with the disease-specific pathology, has been approved for marketing by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) However, as significant data on tofersen's safety and efficacy are required, the evaluation of this treatment is ongoing. This paper introduces the current clinical and commercial status of Tofersen, along with expectations for its approval in Japan.
Insights
Tofersen, a gene-specific therapy for SOD1-familial amyotrophic lateral sclerosis (ALS), is now approved in the US and EU. Ongoing evaluations will determine its full safety and efficacy profile.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Context:
- Familial amyotrophic lateral sclerosis (ALS) research has focused on SOD1 mutations since 1993.
- Over 30 years of research into ALS pathogenesis and therapeutics.
- Tofersen represents a novel gene-specific therapeutic approach targeting SOD1-ALS.
Purpose:
- To introduce the current clinical and commercial status of Tofersen.
- To discuss the ongoing evaluation of Tofersen's safety and efficacy.
- To outline expectations for Tofersen's approval in Japan.
Summary:
- Tofersen, a gene-specific therapy for SOD1-familial ALS, has received marketing approval from the FDA and EMA.
- Further data on tofersen's safety and efficacy are required, and its evaluation is ongoing.
- This paper reviews tofersen's current status and future prospects in Japan.
Impact:
- Provides an overview of a significant advancement in ALS therapeutics.
- Highlights the importance of ongoing clinical evaluation for newly approved gene therapies.
- Informs about the potential availability of Tofersen in the Japanese market.
More Related Videos
06:49A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
Published on: October 6, 2015
11:12Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells
Published on: October 4, 2017
